A comparison of operational definitions for Mild Cognitive Impairment

Manuscript Number: 

21-5548R2

Author(s): 
Lutz Frölich, Michael Hüll, Frank Jessen, Johannes Kornhuber, Piotr Lewczuk, Wolfgang Maier, Oliver Peters, Alexandra Polcher, Eckart Ruther, Michael Wagner, Jens Wiltfang, Steffen Wolfsgruber

Disclosures

Lutz Frölich

  • Nothing to Disclose

Michael Hüll

  • Nothing to Disclose

Frank Jessen

  • Nothing to Disclose

Johannes Kornhuber

  • Nothing to Disclose

Piotr Lewczuk

  • Consulting Fees:
    PL received consultation and/or advisory board honoraria from Fujirebio Europe, AJ Roboscreen, Biogen, and Roche.
    Lecture Fees:
    PL received lecture honoraria from Fujirebio Europe, and Roche.

Wolfgang Maier

  • Nothing to Disclose

Oliver Peters

  • Consulting Fees:
    Dr Peters received consulting fees from Biogen, Noselab and Priavoid. Dr Peters particpated in paid advisory boards from Roche, Novonordisk, Eisai and Griffols.
    Lecture Fees:
    Dr Peters received lecture fees from Neurolive and Medscape.
    Grants
    • Agency: 
      Roche
      Dates: 
      2017-2022
    • Agency: 
      Biogen
      Dates: 
      2017-2022
    • Agency: 
      Eisai
      Dates: 
      2019-2022
    • Agency: 
      Vivoryon
      Dates: 
      2020-2022
    • Agency: 
      Pharmatrophix
      Dates: 
      2018-2021

Alexandra Polcher

  • Nothing to Disclose

Eckart Ruther

  • Nothing to Disclose

Michael Wagner

  • Nothing to Disclose

Jens Wiltfang

  • Nothing to Disclose

Steffen Wolfsgruber

  • Nothing to Disclose